Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents

Molecular and Cellular Endocrinology

Volumn 371, Issue 1-2, 2013, Pages 100-106

  Mast, Natalia ^a   Linger, Marlin ^a   Pikuleva, Irina A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activation; CYP11A1; CYP46A1; Cytochrome P450; Drug target; Inhibition

Indexed keywords

CARBENOXOLONE; CHOLESTEROL; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CLOBENPROPIT; CLOTRIMAZOLE; CYTOCHROME P450; CYTOCHROME P450 46A1; CYTOCHROME P450 INHIBITOR; DESOGESTREL; DEXMEDETOMIDINE; ENZYME ACTIVATOR; HEXACONAZOLE; KETOCONAZOLE; PEMIROLAST; PHOSPHOLIPID; POSACONAZOLE; PREGNENOLONE; RAVUCONAZOLE; RECOMBINANT ENZYME; SELEGILINE; TIZANIDINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG APPROVAL; DRUG DETERMINATION; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME REGULATION; IN VITRO STUDY; LIPID BILAYER; MOLECULAR INTERACTION; PRIORITY JOURNAL; SPECTROSCOPY; STEROIDOGENESIS;

ADRENAL CORTEX HORMONES; CHOLESTEROL; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; ENZYME ACTIVATORS; ENZYME INHIBITORS; HUMANS; PHOSPHOLIPIDS; PREGNENOLONE; STEROIDS;

EID: 84876071960     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.10.013     Document Type: Article

References (31)

1. Berwanger A., Eyrisch S., Schuster I., Helms V., Bernhardt R. Polyamines: naturally occurring small molecule modulators of electrostatic protein-protein interactions. J. Inorg. Biochem. 2010, 104:118-125.
2. Bossche H.V. Inhibitors of P450-dependent steroid biosynthesis: from research to medical treatment. J. Steroid Biochem. Molec. Biol. 1992, 43:1003-1021.
3. Dodds Ashley E.S., Alexander B.D. Posaconazole. Drugs Today (Barc) 2005, 41:393-400.
4. Gigon P.L., Gram T.E., Gillette J.R. Effect of drug substrates on the reduction of hepatic microsomal cytochrome P-450 by NADPH. Biochem. Biophys. Res. Commun. 1968, 31:558-562.
5. Guengerich F.P. Human cytochrome P450 enzymes. Cytochrome P450 2005, 377-530. Kluwer Academic/Plenum Publishers, New York, Boston, Dordrecht, London, Moscow. P.R. Ortiz de Montellano (Ed.).
6. Harvey P.W., Everett D.J. The adrenal cortex and steroidogenesis as cellular and molecular targets for toxicity: critical omissions from regulatory endocrine disrupter screening strategies for human health?. J. Appl. Toxicol. 2003, 23:81-87.
7. Heo G.Y., Liao W.L., Turko I.V., Pikuleva I.A. Features of the retinal environment which affect the activities and product profile of cholesterol-metabolizing cytochromes P450 CYP27A1 and CYP11A1. Arch. Biochem. Biophys. 2012, 518:119-126.
8. Hsu D.K., Huang Y.Y., Kimura T. Liposomal cholesterol binding to steroid-free cytochrome P450scc: effects of fatty acyl and head groups in phospholipids. Endocr. Res. 1985, 11:45-58.
9. Kido T., Arakawa M., Kimura T. Adrenal cortex mitochondrial cytochrome P-450 specific to cholesterol side chain cleavage reaction. Spectral changes induced by detergents, alcohols, amines, phospholipids, steroid hydroxylase inhibitors, and steroid substrates, and conditions for adrenodoxin binding to the cytochrome. J. Biol. Chem. 1979, 254:8377-8385.
10. Lambeth J.D., Kamin H., Seybert D.W. Phosphatidylcholine vesicle reconstituted cytochrome P-450scc. Role of the membrane in control of activity and spin state of the cytochrome. J. Biol. Chem. 1980, 255:8282-8288.
11. Lutjohann D., Breuer O., Ahlborg G., Nennesmo I., Siden A., Diczfalusy U., Bjorkhem I. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. USA. 1996, 93:9799-9804.
12. Mailman R.B., Kulkarni A.P., Baker R.C., Hodgson E. Cytochrome P-450 difference spectra: effect of chemical structure on type II spectra in mouse hepatic microsomes. Drug. Metab. Dispos. 1974, 2:301-308.
13. Mast N., Annalora A.J., Lodowski D.T., Palczewski K., Stout C.D., Pikuleva I.A. Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1. J. Biol. Chem. 2011, 286:5607-5613.
14. Mast N., Charvet C., Pikuleva I.A., Stout C.D. Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain. J. Biol. Chem. 2010, 285:31783-31795.
15. Mast N., Linger M., Clark M., Wiseman J., Stout C.D., Pikuleva I.A. In Silico and Intuitive Predictions of CYP46A1 Inhibition by Marketed Drugs with Subsequent Enzyme Crystallization in Complex with Fluvoxamine. Mol. Pharmacol. 2012, 82:824-834.
16. Mast N., Norcross R., Andersson U., Shou M., Nakayama K., Bjorkhem I., Pikuleva I.A. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry 2003, 42:14284-14292.
17. Mast N., White M.A., Bjorkhem I., Johnson E.F., Stout C.D., Pikuleva I.A. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc. Natl. Acad. Sci. USA 2008, 105:9546-9551.
18. Miller W.L., Bose H.S. Early steps in steroidogenesis: intracellular cholesterol trafficking. J. Lipid Res. 2011, 52:2111-2135.
19. Pikuleva I.A. Cytochrome P450s and cholesterol homeostasis. Pharmacol. Ther. 2006, 112:761-773.
20. Pikuleva I.A., Bjorkhem I., Waterman M.R. Expression, purification, and enzymatic properties of recombinant human cytochrome P450c27 (CYP27). Arch. Biochem. Biophys. 1997, 343:123-130.
21. Pikuleva I.A., Mackman R.L., Kagawa N., Waterman M.R., Ortiz de Montellano P.R. Active-site topology of bovine cholesterol side-chain cleavage cytochrome P450 (P450scc) and evidence for interaction of tyrosine 94 with the side chain of cholesterol. Arch. Biochem. Biophys. 1995, 322:189-197.
22. Pitha J., Irie T., Sklar P.B., Nye J.S. Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci. 1988, 43:493-502.
23. Remmer H., Schenkman J., Estabrook R.W., Sasame H., Gillette J., Narasimhulu S., Cooper D.Y., Rosenthal O. Drug interaction with hepatic microsomal cytochrome. Mol. Pharmacol. 1966, 2:187-190.
24. Russell D.W., Halford R.W., Ramirez D.M., Shah R., Kotti T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu. Rev. Biochem. 2009, 78:1017-1040.
25. Sagara Y., Hara T., Ariyasu Y., Ando F., Tokunaga N., Horiuchi T. Direct expression in Escherichia coli and characterization of bovine adrenodoxins with modified amino-terminal regions. FEBS Lett. 1992, 300:208-212.
26. Sagara Y., Wada A., Takata Y., Waterman M.R., Sekimizu K., Horiuchi T. Direct expression of adrenodoxin reductase in Escherichia coli and the functional characterization. Biol. Pharm. Bull. 1993, 16:627-630.
27. Schenkman J.B., Remmer H., Estabrook R.W. Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol. Pharmacol. 1967, 3:113-123.
28. Seybert D.W., Lancaster J.R., Lambeth J.D., Kamin H. Participation of the membrane in the side chain cleavage of cholesterol. Reconstitution of cytochrome P-450scc into phospholipid vesicles. J. Biol. Chem. 1979, 254:12088-12098.
29. Sheets J.J., Vickery L.E. Proximity of the substrate binding site and the heme-iron catalytic site in cytochrome P-450scc. Proc. Natl. Acad. Sci. USA 1982, 79:5773-5777.
30. Sheets J.J., Vickery L.E. Active site-directed inhibitors of cytochrome P-450scc. Structural and mechanistic implications of a side chain-substituted series of amino-steroids. J. Biol. Chem. 1983, 258:11446-11452.
31. Takikawa O., Gomi T., Suhara K., Itagaki E., Takemori S., Katagiri M. Properties of an adrenal cytochrome P-450 (P-450SCC) for the side chain cleavage of cholesterol. Arch. Biochem. Biophys. 1978, 190:300-306.